Abstract
Erythropoietin (EPO) is a cytokine which is commonly associated with its central role in erythropoiesis. The clinical applications of the recombinant hormone are currently restricted to the treatment of anemia in renal failure and cancer. Recent studies, however, have suggested a new role for EPO as an anti-inflammatory and neuroprotective drug. EPO and its receptor are expressed in neurons, glial cells and brain capillary endothelial cells, and the system is upregulated in conditions of cerebral ischaemia and hypoxia. Animal studies have now established that intracerebroventricular administration of recombinant EPO exerts neuroprotection in models of stroke. The mechanisms appear to involve an upregulation of specific anti-apoptotic and anti-inflammatory pathways. In addition, neurotrophic and angiogenetic effects of EPO may contribute in a long latency protection. Interestingly, also systemic administration of recombinant EPO ameliorates neuronal damage after brain ischaemia, and prevents the loss of autoregulation of cerebral blood flow following experimental subarachnoid haemorrhage. Recombinant human EPO is a safe and non-toxic drug, and clinical studies are currently investigating the neuroprotective potential of EPO in humans.
| Bidragets oversatte titel | Erythropoietin--a new therapy in cerebral ischemia? |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 165 |
| Udgave nummer | 24 |
| Sider (fra-til) | 2477-81 |
| Antal sider | 5 |
| ISSN | 0041-5782 |
| Status | Udgivet - 9 jun. 2003 |
Emneord
- Animals
- Brain Ischemia
- Erythropoietin
- Humans
- Injections, Intraventricular
- Neurons
- Neuroprotective Agents
- Receptors, Erythropoietin
- Recombinant Proteins
- Stroke
FN’s Verdensmål
Dette resultat bidrager til følgende verdensmål
